Docosahexaenoic Acid Increases the Potency of Soluble Epoxide Hydrolase Inhibitor in Alleviating Streptozotocin-Induced Alzheimer ’s Disease-Like Complications of Diabetes

Conclusion In the present study, we demonstrated that sEHI alleviates cognitive and memory impairment associated with diabetes-induced Alzheimer-like complication. The positive effect of sEHI TPPU on memory was associated with a reduction in oxidative stress and inflammation in the brain with a parallel decrease in the mRNA level of APP and activity of AChE. The DHA potentiated the effect of TPPU. Edaravone at a higher dose also alleviated memory impairment via decreasing oxidative stress and inflammation. Author Contributions RP, MA, SA, ML, and SG planned the experiments. RP, NB, KG, MA, and SA performed the experiments. RJ and SG analyzed the data. SG, KG, RJ, and BH wrote the manuscript. All the authors reviewed and approved the manuscript. Funding The research was partly funded by following grants to BH: NIH R01 ES002710 (PI, BH), NIH superfund P42 ES04699 (PI, BH) and NIH counteract U54 NS079202-01 (PI, Lein, P.). Conflict of Interest Statement The University of California, Davis holds multiple patents for the use of soluble epoxide hydrolase inhibitors in humans and companion animals. BH founded EicOsis LLC to facilitate the clinical use of soluble epoxide hydrolase inhibitors. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. References Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R., and Zipp, F. (2007). Neuronal dama...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research